02948nas a2200349 4500000000100000008004100001653001000042653001100052653001100063653000900074653001600083653002500099653002400124653002000148653002400168653001800192653002200210653002300232653001100255653001200266653002200278653003000300653002000330653002200350653001400372100002300386245020800409300001000617490000700627520195000634022001402584 2017 d10aAdult10aFemale10aHumans10aMale10aMiddle Aged10aDeveloping Countries10aProspective Studies10aCost of Illness10aHealth Expenditures10aHealth Policy10aInsurance, Health10aAsia, Southeastern10aIncome10aPoverty10aDelayed Diagnosis10aEarly Detection of Cancer10aHealth Planning10aHealth Priorities10aNeoplasms1 aACTION Study Group00aPolicy and priorities for national cancer control planning in low- and middle-income countries: Lessons from the Association of Southeast Asian Nations (ASEAN) Costs in Oncology prospective cohort study. a26-370 v743 a

BACKGROUND: Evidence to guide policymakers in developing affordable and equitable cancer control plans are scarce in low- and middle-income countries (LMIC).

METHODS: The 2012-2014 ASEAN Costs in Oncology Study prospectively followed-up 9513 newly diagnosed cancer patients from eight LMIC in Southeast Asia for 12 months. Overall and country-specific incidence of financial catastrophe (out-of-pocket health costs ≥ 30% of annual household income), economic hardship (inability to make necessary household payments), poverty (living below national poverty line), and all-cause mortality were determined. Stepwise multinomial regression was used to estimate the extent to which health insurance, cancer stage and treatment explained these outcomes.

RESULTS: The one-year incidence of mortality (12% in Malaysia to 45% in Myanmar) and financial catastrophe (24% in Thailand to 68% in Vietnam) were high. Economic hardship was reported by a third of families, including inability to pay for medicines (45%), mortgages (18%) and utilities (12%), with 28% taking personal loans, and 20% selling assets (not mutually exclusive). Out of households that initially reported incomes above the national poverty levels, 4·9% were pushed into poverty at one year. The adverse economic outcomes in this study were mainly attributed to medical costs for inpatient/outpatient care, and purchase of drugs and medical supplies. In all the countries, cancer stage largely explained the risk of adverse outcomes. Stage-stratified analysis however showed that low-income patients remained vulnerable to adverse outcomes even when diagnosed with earlier cancer stages.

CONCLUSION: The LMIC need to realign their focus on early detection of cancer and provision of affordable cancer care, while ensuring adequate financial risk protection, particularly for the poor.

 a1879-0852